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Introduction: Treatment of ovarian cancer has been long standardized with
the inclusion of surgery and chemotherapy based on platinum and taxanes,
this strategy reaching high remission rates. However, when this treatment
fails, further options are available with little benefit. Since ovarian cancer
has specific immunologic features, actually immunotherapy is under evalua-
tion to overcome treatment failure in patients experiencing recurrence.
Areas covered: Immunogenicity of ovarian cancer and its relationship with
clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strate-
gies are summarized. The clinical trials investigating immunotherapy in
recurrent ovarian cancer patients are reported.
Expert opinion: The results of these clinical trials about immunotherapy are
interesting, but little clinical benefit has been achieved until now. For this
reason, we could conclude that immunotherapy is quite different from other
treatment options and it could change the global approach for recurrent
ovarian cancer treatment. However, to date only fragmentary findings are
available to define the real role of immunotherapy in this setting.
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1. Introduction
Ovarian cancer is the fifth most common cause of cancer-related death in women,
with an estimated incidence in the USA in 2013 of almost 22,000 cases and a
mortality of 14,000 for the current year. According to EUCAN data, the estimated
number of new diagnosis is near to 44,200 with a standardized rate of
12.6/100,000 and a mortality of almost 30,000 per year [1,2]. Ninety percent of
ovarian cancers are epithelial and arise from the epithelium on the ovarian surface
or Mullerian derivatives including the distal Fallopian tube. WHO classification
identifies six principal histotypes: serous, mucinous, endometrioid, clear cell, transi-
tional cell and squamous. Each type can be classified into three prognostic catego-
ries: benign, malignant and intermediate, the latter known as tumors of
borderline malignancy or low malignant potential and atypical proliferative tumors.
Ovarian carcinomas are further sub-classified for their architectural features into
three grades, according to the percentage (< 5%, 5 -- 50% and > 50%) of solid
growth on glandular and papillary component [2].
Treatment of epithelial ovarian cancer is based on the combination of cytoreduc-
tive surgery and combination chemotherapy using taxane and platinum. However, in
our opinion there is a large expectation for improved prognosis in ovarian carcinoma
10.1517/14712598.2014.859671 © 2014 Informa UK, Ltd. ISSN 1471-2598, e-ISSN 1744-7682 103
All rights reserved: reproduction in whole or in part not permitted
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Fr
an
ci
s A
 C
ou
nt
w
ay
 L
ib
ra
ry
 o
f M
ed
ic
in
e 
on
 0
9/
30
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
as a consequence of the use of new biological agents. Adjuvant
chemotherapy for early stage ovarian cancer is still controver-
sial but some studies have shown its benefit under confined
conditions [3]. According to the results of two studies from
the International Collaborative Ovarian Neoplasm group
and the EORTC, patients with IA or IB FIGO stage, non-
clear-cell histology, well-differentiated (G1) tumors, and an
‘optimal’ surgery (performed according to international guide-
lines, with pelvic and retroperitoneal assessment), appear not
to benefit from chemotherapy [4,5].
The standard treatment for patients with advanced ovarian
cancer is maximal surgical cytoreduction (total abdominal
hysterectomy, bilateral salpingo-oophorectomy, pelvic and
para-aortic lymphadenectomy and omentectomy) followed
by systemic platinum-based chemotherapy and, actually, is
reasonable to expect a 5-year survival for 10 -- 30% of
women diagnosed with ovarian cancer at Stage III or
IV [6,7]. Despite the activity of first-line chemotherapy, which
gives response rates up to 80% in first-line treatment, the
majority of patients die because of their recurrent disease.
Therefore, a large proportion of patients are candidates for
second-line treatment. Platinum sensitivity, which is defined
by a response to first-line platinum-based therapy, has been
found to predict the response to subsequent retreatment
with a platinum-containing regimen frequently used for sal-
vage therapy. In general, patients who progress or have stable
disease during first-line treatment or who relapse within
1 month are considered to be ‘platinum-refractory’. Patients
who respond to primary treatment and relapse within
6 months are considered ‘platinum-resistant’, and patients
who relapse > 6 months after completion of initial therapy
are characterized as ‘platinum-sensitive’ [8]. The optimal
treatment for patients with partially platinum-sensitive
recurrent ovarian cancer is not clearly defined. Patients
with platinum refractory and resistant are quite suitable for
novel investigational approaches and studies of drug resis-
tance. Single-agent therapy is considered the standard treat-
ment in these patients [9]. Low response rates are recorded
in these patients with the use of topotecan, docetaxel, oral
etoposide, pegylated liposomal doxorubicin (PLD), gemcita-
bine, ifosfamide and hexamethylmelamine. However, PLD
has favorable pharmacokinetic properties such as a lower
plasma concentration peak, lower clearance, smaller distribu-
tion volume, longer half-life and higher AUC, resulting in a
different and more convenient toxicity and efficacy
profile [10]. One of the most investigated and promising
molecular targeted drugs in ovarian cancer is bevacizumab,
a monoclonal antibody directed against VEGF. VEGF
expression is higher in ovarian cancer tumors than in normal
ovarian tissue or benign ovarian tumors, and increasing
VEGF expression in either cytosolic fractions derived from
ovarian cancer tumors or serum VEGF levels in preoperative
serum is considered to be associated with advanced stage and
worse survival [11]. Recently the anti-VEGF monoclonal anti-
body bevacizumab was studied in combination with carbo-
platin/paclitaxel in Phase III clinical trials for the upfront
setting of advanced ovarian cancer. A statistically significant
increase of progression-free survival (PFS) was observed
when patients received maintenance bevacizumab after
upfront treatment. However, the benefit appears modest
and further studies are needed to clarify the role of this
drug in ovarian cancer treatment [12,13].
2. Mechanisms of immunogenicity and
immunoediting in ovarian cancer
and clinical effects
Human immune system is able to build a number of mech-
anisms to recognize and destroy foreign cells such as those of
malignant tumors with the implication of both the two com-
partments: innate and adaptive [14,15]. First of all ovarian can-
cers express tumor-associated antigens, for example, HER2/
neu [16], MUC1 [17], OA3 [18], membrane folate receptor [19],
TAG-72 [20], mesothelin [21], NY-ESO-1 [22] and sialyl-Tn
[23], which can serve as targets for humoral and cellular
immune responses [24]. The mechanisms of immunosurveil-
lance and immunoescape in cancer patients seem to be quite
complex and not fully explained but they could be summa-
rized as follows. In the immune response to cancer, several
actors play different roles trough three phases: elimination,
equilibrium and escape [25]. The ensemble of these events is
called immunoediting [26]. T cells are the principal actors
of the first two phases (elimination and equilibrium) in
which the immune system recognizes and eliminates cancer
cells with the result of a complete control of cancer that
despite of these mechanisms becomes clinically relevant,
when its cells acquire the capacity of escaping the immune
Article highlights.
. The decision-making for treatment of advanced ovarian
cancer is guided by platinum sensitivity. To date new
therapeutic options have provided further chances
of survival.
. Ovarian cancer can be associated with immunologic
changes, regarding T regulatory lymphocytes,
immunosuppressive cytokines and gd T cells, which have
an impact on clinical outcomes.
. The immunologic strategies, which have been developed
for cancer treatment, include anti-Id therapy, cancer
vaccines, tumor cell vaccines, adoptive cell transfer and
immunomodulation strategies.
. Some of these treatment strategies have been applied
to recurrent ovarian cancer. However, little clinical
benefits were found.
. Immunotherapy in recurrent ovarian cancer has a valid
biologic rationale and interesting perspective. Further
studies are needed to clarify the role of these strategies
in this setting.
This box summarizes key points contained in the article.
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system’s control by suppressing it. The phase of elimination
starts when the growth and developing of cancer’s tissues
induces the release of cytokines which make elements of
the innate compartment (NK, gd-cells and macrophages) to
interact with the surface of the tumor itself. The resulting
production of IFN-g and IL-12 (with a positive feedback)
leads to the tumor killing by suppression of its proliferation
and neoangiogenesis and conduces its cells to apoptosis. In
addition, macrophages and NK cells activated by IFN-g ,
kill tumor cells thus giving the start for the adaptive com-
partment. The dendritic cells (DCs) activated by cytokines
or directly by NKs are located in the tumor site [27]. After
the ingestion of cancer cells’ components, they migrate to
local lymph nodes, where they activate cancer-specific
Th1 (CD4) with the result of the recruitment of cancer-
specific CD8+ CTLs. Th1 CD4+ and CD8+ lymphocytes
migrates in the cancer site and kill cancer cells. For these rea-
sons, the presence of a T cells infiltration is considered as the
‘primum movens’ of the game and it has been also demon-
strated that in the case of ovarian cancer, it has a prognostic
significance [28]. In addition, CD3+ CD56+ cells, containing
the NK-like T cytotoxic cells, play a role in this phase and
their finding in the ascitic fluid in ovarian cancer patients
seems to correlate with better prognosis [29]. The second
stage, called equilibrium, can last many years. During this
long period tumor cell clones, characterized by a high genetic
instability, mutate generating new antigenic variants without
a complete control by the immune system. Escaping is the
third phase of the game in which cancer cells evade immune
system and become immunologically autonomous and it
could be explained by the presence of T lymphocytes with
immune-suppressive functions (Treg) and with tumor’s pro-
duction of inhibiting cytokines like IL-10 and TGF-b.
Lower levels of immunogenicity in the phase of escape are
also probably due to a reduced sensitivity to IFN-g , a loss
of MHC in tumor’s surface and a higher level of NKG2D
ligands (MICB) [30,31]. The presence of a high count of
Treg cells has been correlated with a reduced level of IL-2,
IFN-g and TNF-b [32]. Other mechanisms of immune-
escaping in ovarian cancer were found in a study by
Raspollini et al. in which the presence of gd-T lymphocytes
infiltration in 95 advanced ovarian carcinomas, is correlated
with a worse prognosis, confirming the immune-inhibiting
role of these cells [33]. Clinical studies have also shown effi-
cacy of immunotherapies already used for other malignan-
cies, in patients with epithelial ovarian cancer that is
interleukin-2 (IL-2) and CTLA-4 antibody [34,35]. These
and other data available in literature confirm the strong con-
nection between the immune system and the natural history
of epithelial ovarian carcinomas: on the basis of such eviden-
ces it seems that therapeutic options for this malignancy
could represent a valid alternative after conventional
chemotherapy regimens.
Many studies have demonstrated spontaneous antitumor
immune responses in patients with ovarian cancers, through
the identification of tumor-reactive T cells and antibodies in
peripheral blood [36,37] and tumor-reactive T cells in tumors
or ascites [38-45], suggesting that ovarian cancers are
intrinsically immunogenic.
It has been observed that in ovarian cancer, the presence
of antitumor immune response by intratumoral infiltrating
T lymphocytes was associated with significantly improved
survival in patients with a complete clinical response after
debulking and platinum-based therapy. This advantage has
been demonstrated in 2003 by Zhang et al. who analyzed
186 frozen specimens from advanced-stage ovarian carcino-
mas to assess the distribution of tumor-infiltrating T cells
(tumor-infiltrating lymphocytes, TILs) with immunohisto-
chemical assays and correlated these data with survival and
PFS. In 58% of the specimens CD3+ tumor-infiltrating
T cells were detected, and the 5 years OS rate was signifi-
cantly superior for patients whose tumors had lymphocytic
infiltration (38 vs 4.5%, p < 0.001). In addition, a substan-
tial advantage in 4 years -- PFS rate has been found for
patients with intratumoral T cells infiltrations (31 vs 8.7%,
p < 0.001). They also observed an association between pres-
ence of TILs and the percentage of complete surgical debulk-
ing, thus suggesting that a good host immune response can
confine tumor’s expansion and infiltration [46]. Several stud-
ies have shown a prevalence of intraepithelial T cells in
tumors with increased proliferation, indicating that
improved outcome is not due to indolent tumors [47].
The intratumor presence of effector T cells, helper and
cytotoxic, is associated with improved survival in patients
with higher numbers of intraepithelial CD8+ T cells com-
pared with patients without intraepithelial CD8 cytotoxic
T cells (median survival 55 vs 26 months) [48,49]. In contrast
to CD8 cytotoxic T cells, the role of CD4 helper T cell infil-
tration is less clear, in fact similar outcomes have been
observed among patients with or without CD4+ T cell stain-
ing of tumors [48,50]. Moreover, high levels of IL-17 are asso-
ciated with greatly improved outcome suggesting that a
subset of CD4 Th cells, called Th17 and producing IL-17,
may have a direct role in eradicating tumors [51]. The presence
of blood NK cell activity in ovarian cancer patients before sur-
gery is considered a predictive factor of improved PFS,
whereas an increase of NK cells in peritoneal and pleural
fluids of metastatic ovarian cancer suggests poorer progno-
sis [52,53]. Although evidence of antibody responses to ovarian
cancer has been shown studies evaluating whether B cell infil-
tration is associated with improved survival show unclear
results [37,50,53-55].
According to the all above reported observations, ovarian
cancers should no longer be considered immunologically inert
tumors. Pilot clinical data indicate that patients with ovarian
cancer can in fact respond to the same immunotherapy
approaches as patients with other immunogenic tumors,
such as melanoma [56]. In the tumor milieu, however, immune
suppressive signals are often dominant, and may prevent
effective clearance of tumor cells by the immune system.
Immunotherapy for recurrent ovarian cancer
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A conspicuous group of immune suppressive factors and cells
halt the generation and clonal expansion of antitumor immu-
nity. Furthermore, tumor cells’ genetic changes allow them to
be ignored by the immune response. Immune suppression
is mediated by factors released from the tumor or by lym-
phoid or myeloid-derived suppressor cells (MDSCs) or regu-
latory cells that infiltrate the tumors. Among these,
CD4 Tregs have an important role in the immune evasion
of ovarian cancers.
Tregs are a heterogeneous T-cell subpopulation whose pri-
mary function is immune regulation by blocking both the
function and the proliferation of activated T cells through
immune-suppressive soluble mediators such as TGF-b and
IL-10 (induced or adaptive Tregs) or by means of cytokine-
or contact-dependent mechanisms (natural Treg cells) [57,58].
Tumors can recruit or induce Treg tumor infiltration as shown
by numerous studies that demonstrate intratumoral localiza-
tion of Tregs in several human cancers; besides, several tumor
types, including ovarian, can increase the numbers of Tregs
in the peripheral blood of cancer patients [59-61].
Curiel et al. evaluated the role of regolatory CD4+
CD25+FOXP3+ T cells (Treg) in 104 patients with ovarian can-
cer. They demonstrated that the exaggerated suppression of
tumor-associated antigen-reactive lymphocytes mediated by
Treg cells may cause the loss of host antineoplastic immunity
and they also showed that increased tumor Treg cells’ amount
is associated with a reduced patients’ survival [62]. Moreover,
Wolf et al. showed improved survival in patients with low levels
of intratumoral Foxp3 Tregs versus patients with high levels
(77 vs 30 months) [63].
DCs, involved in T-cell activation, are not activated by
tumors; human ovarian cancers contain either DC or their
precursors, which could promote both angiogenesis and vas-
culogenesis during tumor growth [64-67]. In particular, the
presence of DC expressing B7-H1 is associated with poor
overall survival (OS) in ovarian cancer, probably by directly
inhibiting T cell proliferation and by promoting the induc-
tion of FoxP3+ Tregs as well [68-71]. Thus, the DC population
could represent a therapeutic target in ovarian cancer; in this
regard, recent murine modeling studies demonstrate
improved anti-tumor immunity following specific depletion
of DCs [72].
Even neutrophils could have a potential immune deregulat-
ing role in ovarian cancer. A study carried out by Klink and
colleagues evaluated the interactions between neutrophils
and ovarian cancer cells [73] and recent studies showed that
elevated neutrophil-to-lymphocyte ratio [NLR] is an indepen-
dent prognostic factor associated with an increase in disease
recurrence in several cancers [74-78]. Cho et al. showed that
patients with advanced ovarian cancer and high preoperative
NLR had decreased OS compared to patients with low
NLR [75]. In the future, the neutrophils may become targets
for immune-based therapies for advanced and metastatic
ovarian cancer.
3. Results of clinical trials on immunotherapy
for recurrent ovarian cancer
Although the improvement in clinical outcome from surgery
and chemotherapy in ovarian cancer patients, the most of
the patients relapse after first-line therapy. The evidence of
immunogenicity for ovarian cancer prompted innovative
immunotherapy for recurrent ovarian cancer to extend the
survival of these patients.
Adoptive immunotherapy is one of the most studied kinds of
immunotherapy. Cancer immunotherapy is dependent on the
presence of TILs with appropriate homing and effector func-
tions. Adoptive T cell immunotherapeutic strategies utilizing
naturally occurring tumor-reactive T cells are limited by the
availability of such T cells for administration and the downregu-
lation of MHC Class I molecules and antigen processing
machinery by the tumor. To overcome this problem chimeric
antigen receptor (CAR)-T lymphocytes were used in preclinical
and clinical studies. CARs bypass a common immune evasion
mechanism of tumor cells, the downregulation of MHC-I and
antigen presentation, and provide to use engineered T cells
without MHC restriction and with potent costimulatory sig-
nals. A Phase I clinical trial studied the safety, feasibility and
preliminary activity of the adoptive transfer of autologous
T cells transduced with CAR recognizing the folate receptor-
alpha (FRa), and carrying the CD3z domain along with
the4-1BB costimulatory signaling domain to address the issue
of persistence of FRa-specific CAR-T cells [79]. Enrolled
patients had FRa-positive epithelial ovarian carcinoma stages
II -- IV relapsed after two or more chemotherapy regimens.
Folate receptor is a target antigen expressed in 90% of epithelial
ovarian carcinoma and its expression is not significantly altered
even after chemotherapy, for these reasons it appears to be a safe
target. All enrolled subjects received untransduced autologous
peripheral blood lymphocytes intravenously to contain the
exponential expansion of CAR-T cells. This study is actually
ongoing. Previous findings in CLL patients showed no acute
toxic effects and after 6 months from the infusion CAR-T cells
persisted at high level in the blood and bone marrow continued
to express the CAR.
A recent study evaluated in recurrent ovarian cancer
patients a combinatorial approach encompassing DC-based
autologous whole tumor vaccination and anti-angiogenesis
therapy, combined with subsequent adoptive transfer of autol-
ogous vaccine-primed CD3/CD28-co-stimulated lympho-
cytes. Tumor lysate was obtained from prior cytoreductive
surgery treatment. Subsequently intravenous bevacizumab
and oral metronomic cyclophosphamide were delivered,
followed by bevacizumab plus vaccination with DCs pulsed
with autologous tumor cell lysate supernatants, lymphodeple-
tion and transfer of autologous vaccine-primed T cells. Six
patients receiving this vaccine showed a good tolerability. In
four patients antitumor immune response was demonstrated,
G. Bronte et al.
106 Expert Opin. Biol. Ther. (2014) 14(1)
Ex
pe
rt 
O
pi
n.
 B
io
l. 
Th
er
. D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
Fr
an
ci
s A
 C
ou
nt
w
ay
 L
ib
ra
ry
 o
f M
ed
ic
in
e 
on
 0
9/
30
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
and they experienced clinical benefits. Lymphodepletion and
adoptive T cell transfer was applied in three out of these
four patients. It resulted in a durable reduction of circulating
regulatory T cells and increased CD8+ lymphocyte counts [80].
A Phase II study tested a maintenance immunotherapy
based on IL-2 and 13-cis-retinoic acid (RA) that improved
the tumor associated immunodeficiency and decreased vascu-
lar endothelial growth factor (VEGF), which is a cytokine that
negatively influences the function of the immune system and
it is associated with poor OS. IL-2 has pleiotropic activities on
cell-mediated and humoral immunity, improving T cell
proliferation, increasing the generation of cytotoxic
T lymphocytes (CTL) and inducing both the activation of
T and B cells and the activity of natural killer cells (NK). Ret-
inoids increase IL-2 receptors and peripheral blood lymphoid
cells expressing surface markers for T-helper cells, and cooper-
ate with IL-2 to increase the production of IFN-g . After
6 months of immunotherapy, the lymphocyte count, the
number of NK cells and the CD4+/CD8+ ratio increased in
patients with a partial response and stable disease. Patients
with disease progression did not show any change in lympho-
cyte count. NK cells and the CD4+/CD8+ values continued to
be high after 1 and 5 years only in patients who were progres-
sion-free. The therapy substantially decreased VEGF levels,
also after 5 years. The progression was accompanied by a sub-
stantial decrease of lymphocyte and NK count and by increase
of VEGF. After a median follow-up of 46.9 months (mini-
mum, 34 months for living patients), 29 patients were alive
and 21 patients were progression-free. The median PFS was
23.2 months, and the median OS was 52.8 months [81].
In another Phase II study, IL-2 is used to promote NK cell
expansion. It evaluated the tumor response and in vivo expan-
sion of allogeneic NK cells in recurrent ovarian and breast
cancer. Twenty patients (14 ovarian, 6 breast) were first
treated with fludarabine and cyclophosphamide or radiother-
apy to increase a lymphodepletion. NK cells were taken from
a haplo-identical related donor and incubated with
IL-2 before infusion. In the weeks after, a subcutaneous
IL-2 infusion was given to promote the NK cell expansion.
They obtained a mean NK cell dose and donor DNA was
detected 7 days after NK cell infusion, especially in patients
that underwent to depletive radiotherapy (85 vs 69%). After
14 days, regulatory T cells (p = 0.03) and serum
IL-15 levels (p £ 0.001) were increased. Studies to increase
in vivo NK cell persistence and expansion are still needed [82].
A Phase I/II study considered therapeutic effects of adop-
tively transferred IL-10- and IFN-g-producing CD4 effector
cells in patients with recurrent ovarian cancer. Autologous
CD4 effector cells were stimulated ex vivo by MUC1-peptide
and IL-2 and then intraperitoneally reinfused. One out of
four enrolled patients with recurrent disease was disease-free
after 16 months. In patients with long survival high levels of
systemic CD3(+)CD4(+)CD25(+) and CD3(+)CD4(+)
CD25(-) T cells were found. Such cell populations among
these patients contained variable levels of ‘Inducible’ Tr1
[CD4(+)CD25(-)FoxP3(-)IL-10(+)] and ‘Natural’ [CD4(+)
CD25(+)CD45RO(+)FoxP3(+)] regulatory T cell numbers
and ratios that were associated with prolonged and/or
disease-free survival. Restimulated T cells have a higher sur-
vival and apoptosis-inducing activities because of the increase
of IFN-g production and select TNF family ligands. The
results of the study suggest that the immunotherapy adminis-
tered could stimulate differential systemic regulatory T cell
subpopulations that contribute to long-term tumor immunity
and enhanced memory/effector CD4-mediated therapeutic
potentials [83].
Since one of the most common ovarian cancer localizations
is the peritoneal cavity, different studies exploited intraperito-
neal (IP) delivery for immunotherapy. A pilot study enrolled
seven patients with recurrent ovarian cancer confined to the
peritoneal cavity to test the toxicity and feasibility of IP infu-
sion of tumor-specific CTL. After leukapheresis precursor
lymphocytes were collected and stimulated in vitro with
MUC1. IP infusion was well tolerated and no toxic events
were reported. Survival ranged 2 -- 6 months with no evidence
of disease. Survival did not correlate with the number of infu-
sions. Not statistically significant CA125 reduction was
observed just after the first month of immunotherapy, but it
increased then. The immune activated T cells are induced
only after the first cycle, but there was not any increasing of
it after the successive cycles. Multiple cycles of immunother-
apy seems to be not necessary [84].
Malignant ascites is frequently observed in association with
peritoneal localization. In the 90% of ascites fluid the ovarian
tumor cells overexpress the epithelial cell adhesion molecule
(EpCAM), which is not expressed in the other peritoneal cells.
For this reason, it could be a good target for IP immunother-
apy. Catumaxomab (anti-EpCAM  anti-CD3) is a trifunc-
tional monoclonal antibody with two different specificities
binding simultaneously to EpCAM on tumor cells and the
CD3-antigen on T cells. Moreover, this monoclonal antibody
selectively binds to human FcgI and III-receptors on accessory
cells, but not to the inhibitory FcgII receptor expressed on B
cells. These binding specificities of catumaxomab induce a
simultaneous activation of different immune cell types at the
tumor site, resulting in an antitumor activity. A multicenter
Phase I/II study investigated tolerability and efficacy of IP
catumaxomab infusion in recurrent ovarian cancer patients.
Twenty-three patients, with symptomatic malignant ascites
refractory to previous treatments, were enrolled after the
confirmation of EpCAM overexpression on tumor cells.
Safety profile appeared acceptable. The immunoreactions
against tumor cells induced cytokine release, which was
responsible of adverse event. The most frequent side effects
were: fever (83%), nausea (61%) and vomiting (57%). Catu-
maxomab induced effective tumor cell destruction, as demon-
strated by a reduction of EpCAM positive tumor cells in
ascites fluid, with decreased ascites accumulation [85]. More
recently a randomized Phase II/III trial showed similar data.
The subjects were randomized (2:1) to paracentesis plus IP
Immunotherapy for recurrent ovarian cancer
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catumaxomab or paracentesis alone. The patients in the para-
centesis plus catumaxomab group experienced a statistically
significant prolongation of puncture-free-survival and of the
time to next paracentesis. Moreover, it was observed a reduc-
tion of both symptoms and ascites, and also the level of
EpCAM povitive cells in the ascites fluid was reduced. OS,
a secondary endpoint, was prolonged in about 50% of the
patients treated with catumaxomab [86].
Over the last decade anti-idiotypic monoclonal antibodies
were studied as anti-cancer immunotherapy. The term idio-
type (Id) means the typical antigenic determinant of the anti-
body variable part region that allows distinguishing Ig binding
to different antigens. Its most immediate application regards
the targeting of tumor antigens, to which the Id is directed.
On these bases anti-Id antibodies were developed to mimic
tumor antigens. This strategy provided a new opportunity
for the treatment of advanced solid tumor including
ovarian cancer.
According to the ‘immune network hypothesis’ epitopes,
the part of the antigens binding antibodies, are transformed
in Id-determinants expressed on antibodies [87]. So an anti-
body takes at the same time the role of an antigen. In partic-
ular, the immunization with an antigen generates an antibody
called Ab1. The latter generates Ab2 antibodies, which will
have an antigenic determinant that mimics the first antigen
and, therefore, may be used as its surrogates. Thus, immuni-
zation with Ab2 can generate a third antibody Ab3 also called
Ab1’ because it recognizes the original antigen identified by
Ab1 (Figure 1) [88].
The tumor-associated antigen CA125, frequently expressed
in ovarian cancer, is an interesting target for two monoclonal
antibodies, Abagovomab and Oregovomab. Abagovomab is a
murine monoclonal anti-idiotypic antibody directed against
the Ca125 antigen. The first Phase I/II multicenter trial
addressed both safety and immunogenicity of abagovomab,
enrolled 119 women affected by ovarian cancer, carcinoma
of the fallopian tube, peritoneal carcinoma, CA125 positive
malignant tumor and relapsed after debulking surgery and
platinum-based chemotherapy. The treatment induced in
81 out of 119 patients an anti-anti-idiotypic immune
response (Ab3), but the development of Ca125 specific anti-
bodies and antibody-dependent cell-mediated cytotoxicity of
Ca125-positive tumor cells were also reported. The treatment
was well tolerated with no serious adverse events. The OS was
19.4 months, but the group of patients which produced a spe-
cific immune response (Ab3) showed a significantly improve-
ment of OS (23.4 months; p < 0.0001) [89]. The MIMOSA
trial, a randomized, double-blind, placebo-controlled, multi-
center trial, was designed to test Abagovomab as maintenance
therapy in epithelial ovarian cancer patients, primary perito-
neal cancer or fallopian tube cancer, with a first clinical remis-
sion. Although the anti-idiotypic antibody vaccine
ACA125 resulted safe and induced an immune response, no
statistical difference were observed in RFS and OS between
the abagovomab-treated and placebo. These recent data are
in contrast to the results of the previous Phase II study [90,91].
In addition, oregovomab was studied as maintenance
mono-immunotherapy after front-line therapy in a Phase III
Anti-idiotype
antibody
(Ab2)
Anti-anti-idiotype
antibody
(Ab3)
Anti-antigen
antibody
(Ab1)
ldiotype
CA
125
ldiotypic network
Figure 1. The immune network hypothesis. The immunization with an antigen (i.e., CA125) generates an anti-antigen
antibody called Ab1, which induces the formation of an anti-idiotype antibody (Ab2). Its antigenic determinant mimics the
first antigen. So it could be used to generate a third antibody Ab3 also called Ab1’ which recognizes the original antigen
identified by Ab1.
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randomized, double-blind, placebo-controlled trial [92]. Ovar-
ian cancer patients with high serum levels of Ca125 were
treated with oregovomab, but no clinically effective benefit
was observed. In fact after a 5-year follow-up there were no
differences in PFS and time to relapse in these two treatment
arms [93]. Although this clinical results oregovomab elicited
tumor-antigen specific T-cell immunity according with the
data of a pilot Phase II study [94].
A stronger immune response was induced by oregovomab if
it is delivered with front-line chemotherapy (carboplatin-
paclitaxel) in advanced ovarian cancer patients. A Phase II
study investigated the immune adjuvant properties of front-
line chemotherapy when combined with oregovomab
immunotherapy [95].
Recently, a recombinant fusion protein composed of an
anti-idiotypic single chain mimicking CA125 connected
with tuftsin by an artificial linker was constructed. This mol-
ecule was tested in mice. It showed stronger immunogenicity
triggering humoral and cellular immune responses, inducing
enhanced production of anti-anti-idiotypic antibodies and
T cell response. Subsequently, a protection against tumor
challenges may be achieved, so that the administration of
Table 1. All studies, including translational researches and Phase I -- III trials, investigating immunological effects
and clinical outcomes of immunotherapy in recurrent ovarian cancer are summarized.
Citation Treatment Phase Immunologic effect Clinical outcomes
Kandalaft
et al. 2012 [79]
Adoptive transfer of
CAR-T cells
I CAR-T cells persisted
at high level in the
blood and bone
marrow continued
to express the CAR
N/A
Kandalaft
et al. 2013 [80]
DC-based vaccination
and anti-angiogenesis
therapy, with subsequent
adoptive transfer of
autologous vaccine-primed
CD3/CD28-co-stimulated
lymphocytes
Translational Durable
reduction of circulating
regulatory T cells
and increased CD8+
lymphocyte counts
N/A
Recchia
et al. 2010 [81]
Interleukin-2 (IL-2) and
13-cis-retinoic acid (RA)
II The lymphocyte count,
the number of NK
cells and the CD4+/CD8+
ratio increased
mPFS: 23.2 months
and mOS: 52.8
months
Geller
et al. 2011 [82]
Infusion of NK cells incubated
with IL-2
II Regulatory T cells (p = 0.03)
and serum IL-15 levels
(p £ 0.001) were increased
N/A
Dobrzanski
et al. 2012 [83]
Adoptively transferred IL-10- and
IFN-g-producing CD4 T cells
I/II The immunotherapy administered
could stimulate differential
systemic regulatory T cells
N/A
Wright
et al. 2012 [84]
IP infusion of tumor-specific CTL Translational The activated T cells are induced
only after the first cycle, but there
was not any increase after
the successive cycles
mOS: 11.5 months
Burges
et al. 2007 [85]
Intraperitoneal immunotherapy
with catumaxomab, a trifunctional
monoclonal antibody
(anti-EpCAM  anti-CD3)
I/II The level of EpCAM povitive cells
in the ascites fluid was reduced
Reduction of symptoms;
OS was prolonged
in about 50% of pts
Reinartz
et al. 2004 [89]
Abagovomab, a monoclonal
anti-idiotypic antibody
against Ca125
II An anti-anti-idiotypic immune
response (Ab3) was induced,
with Ca125 specific antibodies
and ADCC of Ca125-positive
tumor cells
Improvement of
OS: 23.4 months
Grisham
et al. 2011 [90]
Abagovomab, a monoclonal
anti-idiotypic antibody against
Ca125
III Immunologic response similar
to those observed in previous trials
No statistical difference
in RFS and OS
Berek
et al. 2009 [92]
Oregovomab, as maintenance
mono-immunotherapy after
front-line therapy
III Elicited tumor-antigen specific
T cell immunity
No differences in PFS
and time-to-relapse
Braly
et al. 2009 [95]
Oregovomab with
carboplatin-paclitaxel
II The immune responses were
stronger than maintenance
monoimmunotherapy
N/A
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fusion proteins composed of anti-idiotypic antibodies and
tuftsin could be employed as cancer immunotherapy [96].
Table 1 summarizes all the studies reported above about the
role of immunotherapy in recurrent ovarian cancer patients.
4. Expert opinion
Ovarian cancer treatment is still one of the most relevant chal-
lenges of clinical oncology. In fact ovarian cancer of epithelial
origin is usually diagnosed late, when regional or distant
metastases have been already arisen. To date the standard
treatment for advanced ovarian cancer is represented by the
combination of carboplatin and paclitaxel. When this treat-
ment fails because of cancer progression, further treatment
options are chosen according to the treatment-free interval,
which is useful to define platinum sensitivity or resistance.
Various chemotherapy regimens are now available to deal
with platinum resistance. These options allowed reaching bet-
ter disease control against supportive care.
However, new treatment strategies different from chemo-
therapy have been considered to improve disease control, to
increase OS and to offer an effective therapeutic option to
those patients who developed resistance to all the chemother-
apeutic agents actually available. Among these new treatment
strategies immunotherapy represents one of the most contro-
versial. In fact it has been developed since immunologic fea-
tures were identified in tumor tissue and in the blood of
cancer patients. Ovarian cancer also showed to elicit immune
response as supported by some evidences. These include the
tumor-associated antigen expression, which could take the
role of targets for both humoral and cellular immune
response; TILs within the tumor tissue, which are related to
prognosis; immune-suppressive cytokines and Tregs in the
peripheral blood, which are associated with worse prognosis.
Some studies evaluated immunotherapy as adjuvant treat-
ment after surgery. In fact the real aim of vaccination is to pre-
vent the recurrence of cancer during a quiescent phase.
However, many studies evaluated immunotherapeutic
approaches as further treatment option after failure of stan-
dard chemotherapeutic regimens. In this perspective, many
researchers are trying to answer the question about the most
effective role of immunotherapy in the whole strategy to
improve quality of life and survival of the advanced ovarian
cancer patients. In other words we try to clarify whether
immunotherapy could change the therapeutic landscape for
these patients. We reported a wide analysis about the actual
landscape of immunotherapy developed and studied for
recurrent ovarian cancer. On the basis of this analysis, we
could conclude that interesting treatment options have been
developed. However, not relevant clinical results were
observed, but important changes in immunological features
have been observed as a consequence of these treatments. In
particular, IL-2 treatment with RA achieved interesting high
median PFS and OS and effects on immune cells are associ-
ated with prolonged progression-free time. In addition,
catumaxomab obtained prolonged OS, even though symptom
and ascites reduction was the real aim of this study. For anti-
Id immunotherapy an improvement in OS was observed in
patients who produced Ab3 specific immune response as
reported in the first Phase I/II trial with abagovomab. This
finding was not confirmed in subsequent trials. In the other
studies, the development of immune response related to the
kind of immunologic strategy was observed, but clinical end-
points were not clearly defined. In our opinion to achieve sig-
nificant benefit in common clinical endpoints, such as PFS
and OS, the proper clinical setting, the combination with
appropriate cytotoxic treatment and the optimal phase of dis-
ease natural history should be defined. To date the available
trials for immunotherapy in ovarian cancer patients tried to
test the ability to develop specific immunologic changes and
concomitantly affect on common clinical endpoints were
reported. Specific translational studies are needed to establish
when an immune effect could be translated in improvement
of PFS and OS. The effect of cytotoxic drugs on immune
response development by specific strategies has not been
discovered yet.
However the findings that OS could be improved in those
patients experiencing immunologic activation as a conse-
quence of immunotherapy, let us argue that patients who
receive these treatments have to be selected. A possible way
to explore this field could consider the prognostic classifica-
tion according with the development of immune response
during immunotherapy. For those patients who do not expe-
rience significant immunologic changes, immune escape
mechanisms should be evaluated to identify further immuno-
therapy strategies. The main role for this escape could be
attributed to regulatory T cells, but other mechanisms have
to be considered involving co-stimulatory molecules (CD28/
B7, CTLA-4/B7, PD1/PD-L1, PD1/PD-L2, ICOS/ICOS-L,
CD27/CD70, CD30/CD30L, CD40L/CD40, OX40/
OX40L, GITR/GITRL, TIM family molecules) [97]. In fact
as we have found that antitumor immune response could
fail because of immune escape, a specific treatment option
has been developed to overcome these hurdles. The combina-
tion of antitumor immune modulation and the overcoming of
immune escape mechanisms would represent the new pro-
posal for redesigning the immunotherapy treatment strategy
both to prevent and to control ovarian cancer recurrence. In
fact the main goal of these treatments in recurrent ovarian
cancer is to control the disease for as long time as possible
with minimal toxic effects, which could impair quality of
life. Immunologic strategies appear to hold this potential
but they could be integrated with other strategies to avoid
escape. To date interesting results have been achieved in other
malignancies by immunomodulation strategies including the
anti-CTLA-4, anti-PD1 and anti-PD-L1 moAbs. We argue
that in the next years new trials could be designed with these
agents in recurrent ovarian cancer. The findings of an anti-
CTLA-4 antibody in some previously vaccinated metastatic
melanoma and ovarian cancer patients suggest that
G. Bronte et al.
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CTLA-4 blockade increases tumor immunity [98]. More
recently a preclinical study showed that the combination of
the blockade of both PD-1 and CTLA-4 with GVAX vaccina-
tion induced rejection of tumors in a model of colon and
ovarian carcinoma [99]. Actually a Phase II trial is recruiting
ovarian cancer patients for monotherapy with the anti-
CTLA-4 antibody ipilimumab. Anyway anecdotal data from
initial studies about these immunomodulating agents suggest
that to achieve a relevant and prolonged clinical benefit the
immune escape mechanisms have to be blocked.
5. Conclusions
Anticancer treatment in advanced ovarian malignancy reached
high rates of remission. However, the onset of treatment fail-
ure is associated with poor outcomes since further therapeutic
options achieve little clinical benefit. For this reason research-
ers are attempting a general change of treatment strategy for
these patients. Since immunologic phenomena in ovarian can-
cer could impact on outcomes, immune system modulation
has been exploited for the widening of treatment chances.
Cancer vaccines using both tumor antigens and DCs, adop-
tive immune cell transfer and anti-Id antibodies are the
most interesting immunotherapy strategies studied for recur-
rent ovarian cancer. The clinical outcomes are limited, but
the associated immunization let us argue great therapeutic
potential. To date defining its role in the general strategy
has not been possible yet. Next studies will improve these
clinical results by overcoming immune escape mechanisms.
The possibility of using immunotherapy in ovarian cancer is
still restricted to clinical trials.
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